CH50 Assay (50% Hemolytic Complement Test): Principles, Methods, and Applications

The CH50 assay, also known as the 50% hemolytic complement test, is a functional immunoassay that quantifies the total activity of the classical complement pathway by determining the serum dilution that lyses 50% of antibody-sensitized sheep erythrocytes. This technical article explains the assay principle, specimen requirements, testing procedures, interpretation, and clinical and industrial applications of CH50 testing in accredited third-party laboratories and clinical immunology settings.

Technical Overview

The CH50 assay (50% hemolytic complement activity test) is a classical functional immunoassay used to evaluate the overall hemolytic activity of the complement system in serum. The test measures the ability of all nine components of the classical complement pathway (C1q through C9) to act sequentially and form the membrane attack complex (MAC) on the surface of antibody-sensitized sheep red blood cells (SRBC), ultimately causing cell lysis and release of hemoglobin.

The assay endpoint is defined as the highest dilution of test serum that produces 50% lysis of a standardized erythrocyte suspension. The reciprocal of this dilution, corrected by the dilution factor, is reported as CH50 in units per milliliter (U/mL). Because the complement cascade must be intact from C1 to C9 for hemolysis to occur, a markedly reduced or absent CH50 result indicates a deficiency or consumption of one or more complement components, making the assay a highly sensitive functional screen for the entire classical pathway.

Quantitative analysis of the hemolytic reaction follows the von Krogh equation, which linearizes the sigmoidal dose–response relationship between serum concentration and the percentage of hemolysis. Optical density of the released hemoglobin is typically measured at 540–541 nm, and results are compared against a calibration curve constructed from serial serum dilutions. The assay is performed under controlled conditions specified in clinical laboratory immunology guidelines and quality management frameworks such as ISO 15189, which govern medical laboratory competence and result traceability.

Testing Samples

Serum (Preferred Specimen)

Serum is the specimen of choice for CH50 testing. Venous blood is collected into a plain tube without anticoagulant, allowed to clot for 30–60 minutes at room temperature, and centrifuged to separate the serum. Because complement proteins are thermolabile, serum must be separated promptly and frozen at −70 °C or below within approximately 2 hours of collection if testing is not performed immediately.

Plasma

Plasma may be acceptable in validated protocols, but the anticoagulant must be selected carefully. EDTA chelates calcium ions and blocks complement activation in vivo, which can preserve activation products but may alter functional assay results if not controlled. Heparin and certain gel separators can interfere with the hemolytic reaction and should be avoided unless the method has been validated for that matrix.

Sample Handling and Stability

• Store samples at −70 °C or below; complement activity degrades progressively at −20 °C and rapidly at refrigerated or room temperature.
• Avoid repeated freeze–thaw cycles; single-use aliquots are recommended.
• Reject grossly hemolyzed, severely lipemic, or contaminated specimens, as endogenous hemoglobin and turbidity interfere with spectrophotometric reading at 541 nm.
• Ship frozen samples on dry ice with temperature monitoring to preserve functional integrity.
• Typical minimum volume is 0.5–1.0 mL of serum, depending on whether additional complement component assays are requested.

Testing Items

Core and related testing items commonly offered alongside the 50% hemolytic complement assay include:

• CH50 (total hemolytic complement activity, classical pathway) — the primary functional assay.
• AH50 (alternative pathway hemolytic activity) — performed with rabbit erythrocytes to evaluate the alternative complement pathway; combined CH50/AH50 testing helps localize pathway-specific deficiencies.
• Quantitative complement components — C3, C4 and other factors measured by immunoturbidimetry, nephelometry, or ELISA.
• Complement activation markers — C3a, C5a, Bb, and SC5b-9 (soluble membrane attack complex) for assessing in vivo complement activation.
• Autoantibody panels — C1q-binding immune complex assays and complement-fixing autoantibodies when immune-complex-mediated complement consumption is suspected.
• Hemolysis ratio testing for medical devices — hemocompatibility evaluation of blood-contacting devices performed in accordance with ISO 10993-4, which is mechanistically related but methodologically distinct from serum CH50 testing.

Testing Methods

Classical Tube Dilution Method

The reference technique involves preparing serial two-fold dilutions of patient serum in buffered isotonic medium, adding a fixed volume of sheep erythrocytes sensitized with optimal concentrations of rabbit or goat anti-sheep erythrocyte antibody (hemolysin), and incubating at 37 °C for 30–60 minutes with intermittent mixing. After centrifugation, hemoglobin release in the supernatant is measured spectrophotometrically at 540–541 nm against a 100% hemolysis control (cells lysed with water or ammonium chloride) and a blank control. The von Krogh transformation is applied to plot log[x/(1−x)] against serum dilution, and the dilution corresponding to 50% hemolysis is interpolated to calculate CH50 in U/mL.

Microplate Adaptation

The assay can be miniaturized to 96-well microplates to reduce reagent consumption and enable batch processing. Photometric reading is performed with a plate reader, and calculation software applies the same von Krogh linearization. Microplate versions improve throughput while retaining correlation with the tube method when properly validated against reference materials.

Liposome- and Particle-Based Automated Assays

Modern alternatives replace erythrocytes with liposomes encapsulating a reporter enzyme. Complement activation by the classical pathway releases the reporter, producing a colorimetric signal proportional to total complement activity. These assays are adaptable to automated clinical chemistry analyzers, eliminate donor-cell variability, and offer better precision and lot-to-lot consistency.

ELISA and Immunochemical Alternatives

• ELISA-based complement activity assays detect terminal complex formation using immobilized immune complexes and anti-neoepitope antibodies.
• Immunoturbidimetric and nephelometric assays quantify individual proteins (C3, C4) but measure antigenic mass rather than functional capacity.
• Functional and quantitative assays are complementary: a normal C3/C4 with an absent CH50 strongly suggests a terminal component (C5–C9) deficiency.

Quality Control and Method Validation

• Run calibrators, normal and abnormal controls, and 100%/0% hemolysis controls with each batch.
• Optimize hemolysin sensitization using checkerboard titration to ensure antibody excess.
• Standardize erythrocyte concentration by hematocrit or cell counting to ensure an accurate 50% endpoint.
• Validate precision, linearity, and reference intervals in accordance with the laboratory's quality system and applicable ISO 15189 requirements.
• Establish laboratory-specific reference intervals (commonly approximately 26–60 U/mL, depending on method and population).

Applications

Clinical Diagnosis and Monitoring

• Detection of classical and terminal complement pathway deficiencies (C1–C9), which predispose patients to recurrent neisserial infections and immune complex disease.
• Monitoring disease activity in systemic lupus erythematosus (SLE), where falling CH50 with reduced C3/C4 indicates active immune complex deposition and complement consumption.
• Evaluation of glomerulonephritis, cryoglobulinemia, vasculitides, and rheumatologic disorders involving complement activation.
• Supporting assessment of hereditary angioedema (C1 inhibitor deficiency), paroxysmal nocturnal hemoglobinuria, and complement-mediated hemolytic uremic syndrome.
• Monitoring patients receiving complement-inhibiting biopharmaceuticals, where CH50 suppression confirms pharmacodynamic activity.

Pharmaceutical and Biotechnology Development

• Immunogenicity evaluation of biologics: complement-fixing anti-drug antibodies can be flagged by CH50 changes.
• Pharmacodynamic and bioactivity testing of complement inhibitors and biosimilar candidates in accordance with ICH-aligned development programs.
• Complement activation testing (C3a, C5a, SC5b-9, CH50) for infusion reactions and CARPA (complement activation-related pseudoallergy) risk assessment of nanomedicines and contrast agents.

Medical Device and Material Hemocompatibility

• While device hemocompatibility uses direct and indirect hemolysis ratio tests under ISO 10993-4, complement activation assays complement these studies to fully characterize blood-device interaction.
• Research applications in transfusion medicine, vaccine adjuvant evaluation, and immunotoxicology studies.

FAQ

Q: What does a low CH50 result mean?

A low CH50 indicates reduced total classical pathway activity, caused either by consumption (active autoimmune disease, immune complex deposition, infection, sepsis) or by inherited deficiency of a single complement component. Absent CH50 with normal C3 and C4 strongly suggests a terminal pathway (C5–C9) deficiency and warrants component-level testing.

Q: What is the difference between CH50 and C3/C4 measurements?

CH50 is a functional assay that requires every classical pathway component to be present and active, whereas C3 and C4 tests are quantitative antigenic measurements of individual proteins. A patient may have normal antigen levels but impaired function, or vice versa; the two approaches are therefore complementary.

Q: Why is sample handling so critical for CH50 testing?

Complement proteins degrade rapidly ex vivo through ongoing activation and thermal instability. Delayed separation, warm storage, or repeated freeze–thaw cycles falsely lower CH50. Strict adherence to rapid processing and −70 °C storage is essential for accurate results.

Q: How are CH50 and AH50 results interpreted together?

Low CH50 with normal AH50 points to a classical pathway defect (C1, C2, C4, or C1 inhibitor); low AH50 with normal CH50 suggests an alternative pathway defect (factor D, properdin, factor B); low values in both assays indicate a terminal component (C5–C9) deficiency or C3 deficiency.

Q: Can the assay be affected by pre-analytical interference?